Text Size
2 studies found for:    RENAL CANCER E7080

Modify this search | How to Use Search Results

Show Display Options
Rank Status Study
1 Recruiting A Study of E7080 Alone, and in Combination With Everolimus in Subjects With Unresectable Advanced or Metastatic Renal Cell Carcinoma Following One Prior Vascular Endothelial Growth Factor (VEGF)-Targeted Treatment
Condition: Metastatic Renal Cell Carcinoma
Interventions: Drug: E7080;   Drug: Everolimus;   Drug: E7080 plus Everolimus
2 Recruiting A Multicenter, Open-Label, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib (E7080) Versus Sorafenib in First-Line Treatment of Subjects With Unresectable Hepatocellular Carcinoma
Condition: Hepatocellular Carcinoma (HCC)
Interventions: Drug: E7080;   Drug: Nexavar
To Top

† Indicates status has not been verified in more than two years